Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains.

The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03497845
Study type Interventional
Source Biomedical Advanced Research and Development Authority
Status Active, not recruiting
Phase Phase 2
Start date March 15, 2018
Completion date September 2, 2019

See also
  Status Clinical Trial Phase
Completed NCT00489931 - Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally Phase 1
Completed NCT01910519 - Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) Phase 2
Completed NCT01086657 - An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re... Phase 1
Completed NCT00408109 - Safety Study of Avian Flu Vaccine Phase 1
Completed NCT02107807 - Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine Phase 3